Trials / Available
AvailableNCT04830202
Expanded Access to Telisotuzumab Vedotin
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- AbbVie · Industry
- Sex
- —
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Telisotuzumab vedotin prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Telisotuzumab vedotin | Intravenous Infusion |
Timeline
- First posted
- 2021-04-05
- Last updated
- 2026-02-06
Source: ClinicalTrials.gov record NCT04830202. Inclusion in this directory is not an endorsement.